Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study-Reference-Cited by-同舟云学术

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study

Published:2013-03 Issue:1 Volume:1 Page:51-60
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Vogelmeier Claus F,Bateman Eric D,Pallante John,Alagappan Vijay KT,D'Andrea Peter,Chen Hungta,Banerji Donald

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference29 articles.

1. Inhaled corticosteroids in COPD: the case against;Suissa;Eur Respir J,2009

2. General practitioners' adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study;Jochmann;Swiss Med Wkly,2010

3. Practice patterns in the management of chronic obstructive pulmonary disease in primary practice: the CAGE study;Bourbeau;Can Respir J,2008

4. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study;Vogelmeier;Respir Med,2008

5. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD;Cazzola;Pulm Pharmacol Ther,2010

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overuse of long-acting β ₂ -agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns;Postgraduate Medicine;2023-11-17

2. The Clinical Characteristics and Outcomes in Non-Frequent Exacerbation Patients with Chronic Obstructive Pulmonary Disease in the Chinese Population;International Journal of Chronic Obstructive Pulmonary Disease;2023-08

3. Association of IL4RA polymorphism in predicting susceptibility toward chronic obstructive pulmonary disease;Pharmacogenomics;2023-07

4. Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers;JAMA Internal Medicine;2023-07-01

5. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease;Cochrane Database of Systematic Reviews;2023-06-05